Dr. Paula A. Johnson Joins Abiomed Board of Directors
Abiomed (NASDAQ:ABMD) announces the appointment of Paula A. Johnson, MD, MPH, to the Abiomed Board of Directors, effective immediately. Dr. Johnson will serve as a member of the Governance and Nominating Committee of the board. Following the appointment of Dr. Johnson, the board now comprises nine active directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005332/en/
“Dr. Johnson is known internationally as a leading expert in healthcare, medical research and health policy, especially for her work advancing the health of women,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “She is a visionary physician-researcher who will provide sound guidance as Abiomed builds the field of heart and lung recovery, advances the standard of care and improves outcomes for patients.”
“Abiomed’s dedication to putting patients first and commitment to improving patient outcomes aligns closely with my own convictions,” said Dr. Johnson. “I’m looking forward to joining the board of directors and helping Abiomed bring advanced medical technology to even more patients around the world.”
Dr. Johnson is a cardiologist and the 14th president of Wellesley College. Previously, she was the founder and inaugural executive director of the Connors Center for Women’s Health and Gender Biology and was chief of the Division of Women’s Health at Brigham and Women’s Hospital in Boston, where she led research dedicated to furthering knowledge of the biological differences between women and men when treating disease. She also served as a professor of medicine at Harvard Medical School and a professor of epidemiology at the Harvard T.H. Chan School of Public Health. Dr. Johnson is an elected member of the American Academy of Arts and Sciences and the National Academy of Medicine. She has been recognized as a national leader in medicine by the National Library of Medicine, and has received numerous awards and honorary degrees for her contributions to science, medicine and public health. Dr. Johnson received her AB, MD and MPH degrees from Harvard University and trained in internal medicine and cardiovascular medicine at Brigham and Women’s Hospital.
“Dr. Johnson’s appointment reflects Abiomed’s commitment to ensuring that we have leading experts with a broad mix of skills and viewpoints on the board,” said Dorothy E. Puhy, Lead Independent Director of the Abiomed Board of Directors and former executive vice president, chief operating officer and assistant treasurer of Dana Farber Cancer Institute. “Her experience and perspective as a cardiologist, researcher and advocate for improving the health of women will be invaluable as Abiomed enters its next phase of growth.”
Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com .
This press release contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-SENTINELONE14.5.2021 16:02:08 CEST | Press release
SentinelOne Receives Highest Score for the Type C Use Case in the Gartner 2021 Critical Capabilities for Endpoint Protection Platforms
NY-WIPRO-LIMITED14.5.2021 14:24:13 CEST | Press release
Wipro Limited Appoints Tulsi Naidu to Its Board
REPLY14.5.2021 12:51:06 CEST | Press release
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 2021
TN-PMC-BIOGENIX14.5.2021 11:02:11 CEST | Press release
PMC Biogenix Announces Price Increase on Armoslip® and Kemamide® Fatty Amides
MAVENIR14.5.2021 09:02:13 CEST | Press release
Mavenir Wins Award for Multi-G Open RAN Small Cell Solutions
CO-SWIMLANE13.5.2021 22:32:08 CEST | Press release
Swimlane and Elastic Partner to Deliver an Extensible Framework for Security Operations Teams
NY-IFF13.5.2021 22:17:06 CEST | Press release
IFF Achieves Key 2020 Sustainability Goals
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom